TACH-101 is under clinical development by Tachyon Therapeutics and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TACH-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TACH-101 overview

TACH-101 (formerly QC8222) is under development for the treatment of solid tumors including advanced or metastatic cancer, metastatic colorectal cancer (CRC), esophageal cancer, gastric cancer, breast cancer, triple-negative breast cancer and Diffuse large B-cell lymphomas including germinal-center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL). It is administered through oral route. The drug candidate acts as pan-KDM4 epigenetic regulator.

Tachyon Therapeutics overview

Tachyon Therapeutics is a biotechnology company involved in therapeutics for the treatment of advanced cancers. Tachyon Therapeutics is headquartered in Houston, Texas, the US.

For a complete picture of TACH-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.